New painkiller molecule: a Hérault company could soon move on to clinical trials

Fabien Granier, fondateur de Biodol Therapeutics. JM – JM

À Montarnaud, la biotechnologie médicale avance avec FGHI, Colcom et Biodol Therapeutics, des sociétés partenaires de la recherche publique.

Will Biodol Therapeutics Hit the Jackpot ? The medical biotech company, which continues to work on a new painkiller molecule, could soon move on to human clinical trials after years of development and the filing of its first patents nearly 10 years ago. One thing is certain, the moment of truth is approaching. “We will finally move towards demonstrating the non-toxic nature of the phase 1 molecule. If it goes well, which should be the case, we will begin the phases of demonstrating the mechanisms of this pain-relieving compound in humans”, confirms Fabien Granier, president of the company launched in 2015 and based in Montarnaud since early 2024.

200% Deposit Bonus up to €3,000 180% First Deposit Bonus up to $20,000

A lead from the research labs

Back to the genesis. The company based is from“of a maturation of Inserm of Montpellier, of the Institute of Neurosciences of Montpellier and of the University of Strasbourg. We are developing small molecules against neuropathic pain. We started with an innovation from the research laboratories that we have “matured” until identifying small molecules with therapeutic vocation”, recalls the Gignacois.

The hope of a valorization by a pharmaceutical group

Almost 10 years were necessary to reach the gates of the clinical phase, “not counting the work, well upstream, of my academic colleagues who had initiated the fundamental research”. In total, nearly €16 million was raised for this project, in which funds were invested, without absolute certainty, but which could ultimately be largely valued by a pharmaceutical group.

A virtuous circle to the patient

The patents were filed jointly by the company Biodol Therapeutics and public research organizations. “If it works, it will also have a return on the research organizations that will be able to reinvest in basic research. It is a whole life cycle of innovation. A virtuous loop goes all the way to the patient”.

 

The territory of the CCVH: center of gravity of innovation

" We are not going to deny the attractiveness of the territory. But if I had been told that one day biotech companies would come and set up in the territory, I would not have believed it immediately. And yet!”, savors Philippe Salasc, vice-president of the CCVH delegate for economic development. Because both the economic biotope of the Valley and the support of the CCVH which led Fabien Granier to set up the companies FGHI, Colcom and Biodol Therapeutics in Montarnaud in January 2024. An ideal center of gravity for innovation, between quality of life and proximity to the universities and Inserm in Montpellier.

In these same premises, Fabien Granier also runs the company FGHI, a consulting and support company for innovative health projects. In Montarnaud, the young fifty-year-old is multiplying projects “we are pushing a project in oncology on the treatment of colorectal cancers and we are also collaborating on tissue engineering to make stem cell differentiation”. Enough to advance the treatments of the future.

I subscribe to read the rest